WallStSmart

Indaptus Therapeutics Inc (INDP)vsRevolution Medicines Inc (RVMD)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 23/100 (F).

INDP

Avoid

17

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 3.5
Piotroski: 1/9Altman Z: -18.54

RVMD

Avoid

23

out of 100

Grade: F

Growth: 3.7Profit: 2.5Value: 6.7Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for INDP.

RVMDUndervalued (+89.8%)

Margin of Safety

+89.8%

Fair Value

$1883.88

Current Price

$166.87

$1717.01 discount

UndervaluedFair: $1883.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INDP0 strengths · Avg: 0/10

No standout strengths identified

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.279/10

Conservative balance sheet, low leverage

Areas to Watch

INDP4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$439.70M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
15.0x4/10

Trading at 15.0x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : INDP

INDP has a balanced fundamental profile.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : INDP

The primary concerns for INDP are Revenue Growth, EPS Growth, Market Cap.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

RVMD carries more volatility with a beta of 1.43 — expect wider price swings.

INDP is growing revenue faster at 0.0% — sustainability is the question.

INDP generates stronger free cash flow (-1M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RVMD scores higher overall (23/100 vs 17/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Indaptus Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Indaptus Therapeutics Inc. is a pioneering biotechnology firm focused on advancing immunotherapies that aim to transform cancer treatment paradigms. Utilizing its proprietary platform, the company enhances the immune system's capacity to identify and eliminate tumor cells, thereby improving therapeutic efficacy and patient outcomes. With a robust pipeline of clinical candidates aimed at addressing critical unmet needs in oncology, Indaptus is strategically positioned for growth in a competitive market. By fostering collaborations with leading research institutions and a commitment to scientific innovation, Indaptus aspires to emerge as a key player in the biopharmaceutical sector.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?